R&D | February 18, 2026
Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
Subscribe To Our Newsletter & Stay Updated
